Yoshizato et al. reported that NRAS, TP53, and CBL mutations and 17p loss of heterozygosity are strongly associated with poor prognosis in adult patients with MDS undergoing transplantation therapy28. The gene discussed is TP53; the disease is myelodysplastic syndrome.